Phathom Pharmaceuticals, Inc. (PHAT) — Financial statements
Income statement, balance sheet, and cash flow for Phathom Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 175↑216.9% | 55↑8001.5% | 0.68 | 0.00 | 0.00 | |
| Cost of Revenue | 23↑183.4% | 8↑4674.3% | 0.17↓73.1% | 0.62↑19.0% | 0.52 | |
| Gross Profit | 153↑222.6% | 47↑9080.4% | 0.52↑183.1% | -0.62↓19.0% | -0.52 | |
| Operating Expenses | ||||||
| R&D Expenses | 33↓3.8% | 34↓31.7% | 50↓30.2% | 71↓1.2% | 72 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 280↓3.8% | 291↑146.5% | 118↑17.5% | 100↑61.3% | 62 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 312↓3.8% | 325↑93.5% | 168↓2.3% | 172↑27.7% | 135 | |
| Total Costs & Expenses | 335↑0.7% | 333↑98.1% | 168↓2.6% | 172↑27.7% | 135 | |
| Operating Results | ||||||
| Operating Income | -160↑42.3% | -277↓65.8% | -167↑3.0% | -172↓27.7% | -135 | |
| Depreciation & Amortization | 0.63↓20.4% | 0.80↑38.3% | 0.58↓7.3% | 0.62↑19.0% | 0.52 | |
| EBITDA | -159↑39.1% | -262↓64.4% | -159↑6.3% | -170↓24.3% | -137 | |
| EBIT | -160↑39.0% | -262↓64.3% | -160↑6.3% | -170↓24.3% | -137 | |
| Interest & Other Income | ||||||
| Net Interest Income | -61↓7.4% | -57↓66.8% | -34↓35.4% | -25↓273.1% | -7 | |
| Interest Income | 7↓53.5% | 15↑92.5% | 8↑269.4% | 2↑5100.0% | 0.04 | |
| Interest Expense | 68↓5.4% | 72↑71.6% | 42↑53.7% | 27↑302.3% | 7 | |
| Non-Operating Income | 0.00↑100.0% | -15↓97.1% | -8↓280.2% | -2↓200.3% | 2 | |
| Other Income / Expenses | -61↓7.7% | -57↓65.9% | -34↓35.6% | -25↓187.2% | -9 | |
| Income Before Tax | -221↑33.8% | -334↓65.8% | -202↓2.0% | -198↓37.4% | -144 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -221↑33.8% | -334↓65.8% | -202↓2.0% | -198↓37.4% | -144 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -221↑33.8% | -334↓65.8% | -202↓2.0% | -198↓37.4% | -144 | |
| Bottom-Line Net Income | -221↑33.8% | -334↓65.8% | -202↓2.0% | -198↓37.4% | -144 | |
| EPS (Basic) | -3.03↑42.7% | -5.29↓34.6% | -3.93↑31.1% | -5.70↓42.5% | -4.00 | |
| EPS (Diluted) | -3.03↑42.7% | -5.29↓34.6% | -3.93↑31.1% | -5.70↓42.5% | -4.00 | |
| Weighted Average Shares | 73↑15.4% | 63↑23.2% | 51↑31.1% | 39↑5.7% | 37 | |
| Weighted Average Diluted Shares | 73↑15.4% | 63↑23.2% | 51↑31.1% | 39↑5.7% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.